Associated tags: Infection, Cell, Injury, Paratriathlon, Roche, VAC2, Cancer, Degenerative disease, Lung cancer, Lineage Cell Therapeutics, Therapy, Auditory neuropathy, Geographic atrophy, Health, Biotechnology, Pharmaceutical, Clinical Trials, TASE, NYSE American, Research, Pharmaceutical industry, Patient, Stem Cells, Lineage, Science, Optical, Genentech
Locations: NEW YORK, ISRAEL, MIDDLE EAST, WA, UNITED STATES, NORTH AMERICA, CALIFORNIA, LOS ANGELES
Research,
Surgery,
Public Relations,
Investor Relations,
Communications,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Science,
Other Science,
SCI,
Regenerative medicine,
Conference,
CIRM,
Caregiver,
Multimedia,
Clinical trial,
Therapy,
Organization,
Person,
Pharmaceutical industry Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM) , to support the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").
Key Points:
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the Company has received an Education Conference II Grant from the California Institute for Regenerative Medicine (CIRM) , to support the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS").
- The 2nd SCIIS builds upon a successful inaugural event held in 2023 and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).
- View the full release here: https://www.businesswire.com/news/home/20240430502008/en/
“This conference was created to foster engagement and collaboration, as well as to bring innovation and modernization to approaches and treatments for spinal cord injury.
- “In certain rare conditions, raising investor awareness can lead to greater investment, which can help to accelerate new treatments.
Biotechnology,
Health,
Stem Cells,
Mallinckrodt,
Sale,
University,
General counsel,
Economics,
Compensated emancipation,
Audit committee,
PJT Partners,
Bachelor of Arts,
Therapy,
Senior advisor,
Asterias,
Management Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs.
Key Points:
- Mr. Kingsley served as Chairman of the Company’s Board of Directors since July 2009, and was a significant contributor in the evolution of the Company into a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs.
- Effective as of April 27, 2024, Michael H. Mulroy, J.D., has been appointed by the Board of Directors to serve as the Chairman of the Board of Directors.
- “Al was exceptionally committed to Lineage and its shareholders, and brought great innovation, leadership, and dedication to others to his work.
- He previously served as Chief Executive Officer and a member of the board of directors of Asterias Biotherapeutics, Inc.
Health,
Stem Cells,
Genetics,
General Health,
Research,
Science,
Biotechnology,
Stem cell,
B cell,
Regenerative medicine,
Agriculture,
Global health,
Lineage,
Madrona Venture Group,
Duke University,
Beckman Research Institute,
City,
Columbia University,
University,
NanoString Technologies,
Fierce,
Doctor of Philosophy,
Investment,
Therapy,
Microbiology,
Partner,
Corporate development,
Pharmaceutical industry Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
Key Points:
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
- Most recently, Dr. Hubbert served in the leadership team at NanoString Technologies .
- “We are excited to add such a talented executive to our management team in the newly created position of VP Corporate Development.
- Dr. Hubbert’s decades of experience in cell therapy, strategic investment, and partnering make her a valuable and welcome addition to the Lineage team,” stated Brian M. Culley, CEO.
Health,
Stem Cells,
Genetics,
Research,
Science,
Biotechnology,
Organization,
Cell,
Regenerative medicine,
Caregiver,
Paralysis,
Lineage,
Quality of life,
Clinical trial,
Therapy,
Multimedia,
SCI,
Human,
Person,
Pharmaceutical industry The 2nd SCIIS builds upon a successful inaugural event held on June 29, 2023, and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).
Key Points:
- The 2nd SCIIS builds upon a successful inaugural event held on June 29, 2023, and will connect a diverse set of stakeholders in the field of spinal cord injury (SCI).
- The 2nd SCIIS will be held on June 26 and 27, 2024 at the Sanford Consortium for Regenerative Medicine in La Jolla, CA.
- "Our aim at Lineage is to improve recovery and mobility by replacing the cells which are destroyed following a spinal cord injury.
- This event will bring together both public and private companies developing new treatment options for people with spinal cord injury, alongside leaders in the spinal cord injury medical and advocacy communities.
Retrieved on:
Wednesday, March 13, 2024
Stem Cells,
Biotechnology,
Health,
Philanthropy,
Pharmaceutical,
Optical,
Research,
Genetics,
Foundation,
Science,
Clinical Trials,
Geographic atrophy,
Patient,
Visual impairment,
Doctor of Philosophy,
MD,
Hyatt Regency Seattle,
Therapy,
RPE,
AMD,
Cell Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit .
Key Points:
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that 24 month results from patients enrolled in a Phase 1/2a clinical study (ClinicalTrials.gov Identifier: NCT02286089 ) of RG6501 ( OpRegen ) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD), will be presented at the 2024 Retinal Cell & Gene Therapy Innovation Summit .
- The meeting will be held May 3, 2024, at the Hyatt Regency Seattle, and is jointly organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute .
- The presentation, “OpRegen® Retinal Pigment Epithelium (RPE) Cell Therapy for Patients with Geographic Atrophy (GA): Month 24 Results from the Phase 1/2a Trial,” will include anatomical and functional data from long-term follow-up in 10 of 12 patients and will be presented by David Telander, MD, PhD , Retinal Consultants Medical Group, on behalf of Roche and Genentech , a member of the Roche Group.
Science,
Biotechnology,
Research,
Pharmaceutical,
Optical,
Surgery,
Health,
Clinical Trials,
DVM,
Survival,
Göttingen,
Ophthalmology,
Doctor of Philosophy,
Therapy,
RPE Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 ( OpRegen ) will be presented at the 2024 Association for Research in Vision and Ophthalmology Annual Meeting (2024 ARVO) .
Key Points:
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that preclinical results as part of a surgical development study evaluating the survival and distribution of RG6501 ( OpRegen ) will be presented at the 2024 Association for Research in Vision and Ophthalmology Annual Meeting (2024 ARVO) .
- The meeting will be held May 5-9, 2024, in Seattle, WA.
- The presentation, “OpRegen engrafts within the retinal pigmented epithelium (RPE) of Gottingen mini-pigs by 4-weeks post-administration via subretinal delivery,” will be presented by Rachel N. Andrews, DVM, PhD, DACVP, Principal Scientist-Pathologist, Safety Assessment, Genentech, a member of the Roche Group, on behalf of Roche and Genentech .
Health,
Stem Cells,
Clinical Trials,
Pharmaceutical,
Optical,
Biotechnology,
Spinal cord,
University,
CIRM,
Roche,
Delivery,
Interest,
Expense,
Partnership,
Food,
Inda,
Genentech,
Geographic atrophy,
Therapy,
Webcast,
AMD,
Patient,
Drug discovery,
Congress,
Survival,
G&A,
IND,
Trial of the century,
Research,
Pharmaceutical industry Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
Key Points:
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
- “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs,” stated Brian M. Culley, Lineage CEO.
- Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:
Positive clinical data presented at 2023 Eyecelerator , 23rd EU RETINA Congress , and 2023 ARVO Annual Meetings.
- Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.
Retrieved on:
Thursday, February 29, 2024
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets.
Key Points:
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2023 financial and operating results on Thursday, March 7, 2024, following the close of the U.S. financial markets.
- Lineage management will also host a conference call and webcast on Thursday, March 7, 2024, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2023 financial and operating results and to provide a business update.
- Interested parties may access the conference call on March 7th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”.
- A live webcast of the conference call will be available online in the Investors section of Lineage’s website.
Retrieved on:
Tuesday, February 13, 2024
Research,
Neurology,
FDA,
Clinical Trials,
Stem Cells,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
SCI,
Spinal cord,
Regenerative medicine,
Person,
Proposition 71,
CIRM,
Delivery,
Injury,
Quality of life,
Food,
Surgeon,
Spine,
Safety,
Inda,
Therapy,
Lineage,
Patient,
Journal,
Ventilation,
Trial of the century,
Pharmaceutical industry Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1 , an investigational allogeneic oligodendrocyte progenitor cell transplant for the treatment of spinal cord injury (SCI).
Key Points:
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1 , an investigational allogeneic oligodendrocyte progenitor cell transplant for the treatment of spinal cord injury (SCI).
- The clearance of our INDa and the initiation of OPC1 clinical testing under our sponsorship represents a significant milestone for this program, and reflects our commitment to developing modern cell therapy product candidates,” stated Brian M. Culley, Lineage CEO.
- We believe these improvements can lead to a safer surgical procedure for surgeons and patients.
- The data from the Phase 1/2a clinical study of OPC1 in subacute cervical SCI is available here and the data from the Phase 1 clinical study of OPC1 in acute thoracic SCI is available here .
Biotechnology,
Public Relations,
Investor Relations,
Health,
Communications,
Clinical Trials,
Security (finance),
Therapy,
Form,
Research,
Prospectus,
Sale Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of 13,461,540 of the company’s common shares at an offering price of $1.04 per common share.
Key Points:
- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of 13,461,540 of the company’s common shares at an offering price of $1.04 per common share.
- The price per share was the closing price of the company’s common shares on NYSE American on February 5, 2024.
- “This offering strategically strengthens our balance sheet, which can aid us in reaching important milestones in the months ahead,” stated Brian M. Culley, Lineage CEO.
- We appreciate the contributions of all parties involved in this transaction and look forward to advancing our product candidates this year.”
The aggregate gross proceeds to Lineage from the offering at the closing were $14.0 million before deducting estimated offering expenses payable by Lineage.
